150 related articles for article (PubMed ID: 38357251)
1. When idiopathic multicentric Castleman disease meets COVID-19: a multicenter retrospective study from China.
Liu Y; Yin X; Xu D; Lv Y; Zhu L; Yang M; Yao Q; Jin J; Huang L; Meng H; You L
Ther Adv Hematol; 2024; 15():20406207241229584. PubMed ID: 38357251
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
3. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
[TBL] [Abstract][Full Text] [Related]
4. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
Ferrero S; Ragaini S
J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
Bedier H; Isnard S; Maedler-Kron C; Routy JP
Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
7. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.
González García A; Fernández-Martín J; Robles Marhuenda Á
Rheumatology (Oxford); 2023 Apr; 62(4):1426-1435. PubMed ID: 35997567
[TBL] [Abstract][Full Text] [Related]
9. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.
Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T
CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary Study on the Characteristic of Plasma Cytokine Profiles in Patients with Idiopathic Multicentric Castleman Diseases].
Ma N; Liu HH; Liu W; Yin Y; Wang LH; Liang ZY; Xu WL; Wang Q; Li Y; Wang MJ; Ou JP; Wang WS; Cen XN; Ren HY; Dong YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1305-1310. PubMed ID: 31418397
[TBL] [Abstract][Full Text] [Related]
11. Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series.
Kojima D; Yamaguchi S; Hashiguchi A; Hayashi K; Uchiyama K; Yoshimoto N; Adachi K; Nakayama T; Nishioka K; Tajima T; Morimoto K; Yoshino J; Yoshida T; Monkawa T; Kanda T; Itoh H
Front Med (Lausanne); 2022; 9():1037032. PubMed ID: 36698794
[TBL] [Abstract][Full Text] [Related]
12. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report.
Han PY; Chi HH; Su YT
World J Clin Cases; 2020 Oct; 8(20):4922-4929. PubMed ID: 33195662
[TBL] [Abstract][Full Text] [Related]
14. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
15. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
16. Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody.
Tomioka Y; Otani S; Tanaka S; Shien K; Suzawa K; Miyoshi K; Yamamoto H; Okazaki M; Sugimoto S; Yamane M; Toyooka S
Surg Case Rep; 2021 Sep; 7(1):209. PubMed ID: 34533616
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine.
Hoffmann C; Wechselberger T; Drexel H; Dertinger S; Dirnhofer S; Pierson SK; Fajgenbaum DC; Kessler A
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298590
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]